DGX - Quest Diagnostics Incorporated

NYSE - Nasdaq Real Time Price. Currency in USD
107.82
-0.11 (-0.10%)
As of 3:24PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close107.93
Open108.08
Bid107.80 x 800
Ask107.81 x 800
Day's Range107.51 - 108.72
52 Week Range95.27 - 116.49
Volume530,825
Avg. Volume863,523
Market Cap14.735B
Beta1.14
PE Ratio (TTM)18.56
EPS (TTM)5.81
Earnings DateOct 17, 2018 - Oct 22, 2018
Forward Dividend & Yield2.00 (1.85%)
Ex-Dividend Date2018-10-04
1y Target Est116.86
Trade prices are not sourced from all markets
  • What Quest Diagnostics’ Valuation Trend Indicates
    Market Realistyesterday

    What Quest Diagnostics’ Valuation Trend Indicates

    In September 2018, of the total 18 analysts covering Quest Diagnostics (DGX), ten analysts have given Quest stock a “buy” or higher rating, and eight analysts have given Quest a “hold” rating. The mean rating for Quest stock is 2.22 with a target price of $116.86 implying an upside potential of 9% over Quest’s closing price of $107.22 on September 18, 2018.

  • Taking Stock of Quest Diagnostics’ Recent Acquisitions
    Market Realist2 days ago

    Taking Stock of Quest Diagnostics’ Recent Acquisitions

    Quest Diagnostics’ (DGX) diagnostic information services (or DIS) business accounts for more than 95% of the company’s total revenues. It is characterized by a high volume of relatively low-dollar transactions. Under DIS, Quest provides clinical testing and other services. Major customer groups for DIS include healthcare insurers, government payers, client payers, and patients.

  • How Quest Diagnostics Is Positioned in 2018
    Market Realist2 days ago

    How Quest Diagnostics Is Positioned in 2018

    Quest Diagnostics (DGX) is a leading provider of diagnostic information services. Quest makes use of its database of clinical lab results to gain diagnostic insights that help to improve healthcare management. Quest’s diagnostics information services business (or DIS) provides data and insights based on routine, non-routine, and advanced clinical testing, as well as anatomic pathology testing and other diagnostic information services.

  • Exploring Quest Diagnostics’ Operational Performance
    Market Realist2 days ago

    Exploring Quest Diagnostics’ Operational Performance

    Quest Diagnostics generated net income of $219.0 million in the second quarter of 2018 as compared with net income of $193.0 million in the second quarter of 2017, which translated into net earnings per share of $1.57 in the second quarter of 2018.

  • The Wall Street Journal7 days ago

    [$$] Provant Health Creditors Object to Sales Process, Financing

    Creditors of Provant Health Solutions are moving to stop both an initial bid and continued financing for the bankrupt company, saying other potential buyers will be discouraged by the process and that too little cash is budgeted to investigate claims. Provant, based in Olathe, Kan., provides services that include sample collection, health-risk screening and on-site flu shots administered by independent contractors. Inc., which does business as Provant, objected to Quest’s lead bid and the protections afforded the company as the so-called stalking horse bidder.

  • Here's Why You Should Hold On to Quest Diagnostics (DGX) Now
    Zacks14 days ago

    Here's Why You Should Hold On to Quest Diagnostics (DGX) Now

    Tough competitive landscape and reimbursement issues are major deterrents to Quest Diagnostics' (DGX) top line in the near term. The company's focus on promising areas to drive growth is a positive.

  • Quest Diagnostics to Speak at the Morgan Stanley Global Healthcare Conference
    PR Newswire14 days ago

    Quest Diagnostics to Speak at the Morgan Stanley Global Healthcare Conference

    SECAUCUS, N.J., Sept. 7, 2018 /PRNewswire/ -- Quest Diagnostics Incorporated (DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York City.  Stephen Rusckowski, Chairman, President and CEO and Mark Guinan, Executive Vice President and CFO will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.

  • PR Newswire15 days ago

    Quest Diagnostics Health Trends™ Study Finds Drug Misuse Rates Remain Constant at High Levels, and Dangerous Opioid-related Drug Combining Is Prevalent

    SECAUCUS, N.J., Sept. 6, 2018 /PRNewswire/ -- More than half (52 percent) of Americans tested in 2017 misused their prescription drugs, the same rate as in 2016, but the epidemic is shifting beyond prescription opioids to encompass other drugs and dangerous drug combinations, finds a new Health Trends™ report released today by Quest Diagnostics (DGX): Drug Misuse in America 2018.

  • Theranos' bloody tale nears end with decision to shut down
    American City Business Journals16 days ago

    Theranos' bloody tale nears end with decision to shut down

    The blood-testing company, based most of its life in Palo Alto, has faced lawsuits from investors, the SEC and criminal charges against founder and former CEO Elizabeth Holmes and former President Ramesh "Sunny" Balwani.

  • Does Quest Diagnostics Incorporated’s (NYSE:DGX) PE Ratio Signal A Buying Opportunity?
    Simply Wall St.23 days ago

    Does Quest Diagnostics Incorporated’s (NYSE:DGX) PE Ratio Signal A Buying Opportunity?

    The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to start learning about core conceptsRead More...

  • The Wall Street Journal24 days ago

    [$$] Bankrupt Provant Health to Sell Assets to Quest Diagnostics

    Provant, based in Olathe, Kan., provides services that include sample collection, health-risk screening and on-site flu shots administered by independent contractors. Provant said it has 326 employees on its payroll but through a network of health professionals did nearly 1 million screenings last year. In 2017, Hooper, founded in 1899, merged with Provant Health Solutions LLC. Hooper and its subsidiaries now do business as Provant Health.

  • Quest Diagnostics Declares Quarterly Cash Dividend
    PR Newswirelast month

    Quest Diagnostics Declares Quarterly Cash Dividend

    SECAUCUS, N.J. , Aug. 17, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly ...

  • Quest Diagnostics Earns Gold Status in American Heart Association's Workplace Health Achievement Index
    PR Newswirelast month

    Quest Diagnostics Earns Gold Status in American Heart Association's Workplace Health Achievement Index

    SECAUCUS, N.J., Aug. 16, 2018 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today announced that it achieved gold status in the American Heart Association's 2018 Workplace Health Achievement Index, ranking the company's workplace health program among the best in the nation. The American Heart Association created the Index with its CEO Roundtable members, a leadership collaborative of more than 40 CEOs from some of America's largest companies who are committed to applying evidence-based approaches to improve their employees' overall health. The Index uses science-based best practices to evaluate the overall quality and comprehensiveness of their workplace health programs.

  • Giants dive into the science of sweat to keep players hydrated
    American City Business Journalslast month

    Giants dive into the science of sweat to keep players hydrated

    The New York Giants and Quest Diagnostics are now focusing on creating hydration plans for each player.

  • 'Ultimately, Elizabeth made the decisions': A look inside Theranos' ineffective board
    American City Business Journalslast month

    'Ultimately, Elizabeth made the decisions': A look inside Theranos' ineffective board

    Court documents give some insight into one of the biggest questions about Theranos: How could its board stand pat as key employees left and allegations emerged about the blood testing company's technology?

  • See what the IHS Markit Score report has to say about Quest Diagnostics Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Quest Diagnostics Inc.

    Quest Diagnostics Inc NYSE:DGX

  • ACCESSWIRE2 months ago

    Free Technical Research on Agilent Technologies and Three More Medical Research Equities

    On Monday, July 30, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Seven out of nine sectors ended Monday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Laboratories & Research equities this morning: Agilent Technologies Inc. (NYSE: A), Co-Diagnostics Inc. (NASDAQ: CODX), Quest Diagnostics Inc. (NYSE: DGX), and Bruker Corp. (NASDAQ: BRKR).

  • New Quest Diagnostics Data Shows Lyme Disease Prevalence Increasing and is Now Present in New U.S. States
    PR Newswire2 months ago

    New Quest Diagnostics Data Shows Lyme Disease Prevalence Increasing and is Now Present in New U.S. States

    - Number of positive tests for Lyme disease increased significantly between 2016 and 2017. - Historically concentrated in Pennsylvania and New England states, Lyme disease has been detected in each of the 50 United States and the District of Columbia. - Outside of the northeastern U.S., California and Florida - states not historically associated with significant rates of Lyme disease - saw the largest absolute increases in positive Lyme disease test results.

  • TheStreet.com2 months ago

    Buy These 3 Risky Biotech Stocks

    There's been a lot of talk on the Street about the biotech sector and how drug makers haven't been bringing the heat in 2018. Just six biotech company IPO launches hit this last week. Two new biotech companies are poised to go public this week.

  • S&P 500’s Top Losses: Whirlpool Declined on July 24
    Market Realist2 months ago

    S&P 500’s Top Losses: Whirlpool Declined on July 24

    The S&P 500’s top losses on July 24 were: Whirlpool (WHR) declined 14.52%. Quest Diagnostics (DGX) declined 8.24%. Nektar Therapeutics (NKTR) declined 5.89%. Hasbro (HAS) declined 4.65%. Centene (CNC) declined 4.5%. Whirlpool